CN112912064B - 用于通过吸入给药的包含rpl554的hfa-134a溶液的药物组合物 - Google Patents

用于通过吸入给药的包含rpl554的hfa-134a溶液的药物组合物 Download PDF

Info

Publication number
CN112912064B
CN112912064B CN201980065895.8A CN201980065895A CN112912064B CN 112912064 B CN112912064 B CN 112912064B CN 201980065895 A CN201980065895 A CN 201980065895A CN 112912064 B CN112912064 B CN 112912064B
Authority
CN
China
Prior art keywords
pharmaceutical composition
liquid pharmaceutical
rpl554
particles
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980065895.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN112912064A (zh
Inventor
皮特·莱昂内尔·斯帕戈
菲利普·A·海伍德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Verona Pharmaceutical Co ltd
Original Assignee
Verona Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verona Pharma Ltd filed Critical Verona Pharma Ltd
Publication of CN112912064A publication Critical patent/CN112912064A/zh
Application granted granted Critical
Publication of CN112912064B publication Critical patent/CN112912064B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201980065895.8A 2018-10-09 2019-10-09 用于通过吸入给药的包含rpl554的hfa-134a溶液的药物组合物 Active CN112912064B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1816447.5 2018-10-09
GB1816447.5A GB2578093B (en) 2018-10-09 2018-10-09 Liquid pharmaceutical composition comprising RPL554 and HFA-134A
PCT/GB2019/052863 WO2020074894A1 (en) 2018-10-09 2019-10-09 Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation

Publications (2)

Publication Number Publication Date
CN112912064A CN112912064A (zh) 2021-06-04
CN112912064B true CN112912064B (zh) 2025-02-14

Family

ID=64394831

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980065895.8A Active CN112912064B (zh) 2018-10-09 2019-10-09 用于通过吸入给药的包含rpl554的hfa-134a溶液的药物组合物

Country Status (27)

Country Link
US (2) US20210379053A1 (cg-RX-API-DMAC7.html)
EP (2) EP3960157A1 (cg-RX-API-DMAC7.html)
JP (2) JP7578587B2 (cg-RX-API-DMAC7.html)
KR (1) KR102960903B1 (cg-RX-API-DMAC7.html)
CN (1) CN112912064B (cg-RX-API-DMAC7.html)
AU (1) AU2019358585B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021006712A2 (cg-RX-API-DMAC7.html)
CA (1) CA3113167A1 (cg-RX-API-DMAC7.html)
CY (1) CY1124943T1 (cg-RX-API-DMAC7.html)
DK (1) DK3820446T3 (cg-RX-API-DMAC7.html)
ES (1) ES2899744T3 (cg-RX-API-DMAC7.html)
GB (1) GB2578093B (cg-RX-API-DMAC7.html)
HR (1) HRP20220053T1 (cg-RX-API-DMAC7.html)
HU (1) HUE057780T2 (cg-RX-API-DMAC7.html)
IL (1) IL282032B2 (cg-RX-API-DMAC7.html)
LT (1) LT3820446T (cg-RX-API-DMAC7.html)
MX (2) MX2021003599A (cg-RX-API-DMAC7.html)
MY (1) MY207302A (cg-RX-API-DMAC7.html)
PH (1) PH12021550767A1 (cg-RX-API-DMAC7.html)
PL (1) PL3820446T3 (cg-RX-API-DMAC7.html)
PT (1) PT3820446T (cg-RX-API-DMAC7.html)
RS (1) RS62775B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202102567UA (cg-RX-API-DMAC7.html)
SI (1) SI3820446T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202200044T1 (cg-RX-API-DMAC7.html)
WO (1) WO2020074894A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202102039B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2773142T3 (es) 2014-05-12 2020-07-09 Verona Pharma Plc Nuevo tratamiento
GB201502260D0 (en) 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound
GB201916915D0 (en) 2019-11-20 2020-01-01 Amr Centre Ltd Compounds
GB2594480A (en) * 2020-04-28 2021-11-03 Verona Pharma Plc New treatment
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
EP4609864A4 (en) * 2022-10-28 2026-02-18 Jiangsu Hengrui Pharmaceuticals Co Ltd PHARMACEUTICAL COMPOSITION CONTAINING AN ISOQUINOLINONE COMPOUND AND RELATED PREPARATION PROCESS
EP4378942A1 (en) 2022-12-02 2024-06-05 Sandoz AG Crystal form of a pde3/4 inhibitor
CN121620356A (zh) 2023-06-26 2026-03-06 维罗纳制药公司 包含恩塞芬汀的颗粒组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105142638A (zh) * 2013-03-15 2015-12-09 维罗纳制药公司 药物组合
CN107406446A (zh) * 2015-02-11 2017-11-28 维罗纳制药公司 嘧啶并[6,1‑a]异喹啉‑4‑酮化合物的盐

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1165558T3 (da) 1999-03-31 2004-02-09 Vernalis Ltd Pyrimido[6,1-a]isoquinolin-4-on-derivater
SI2603509T1 (sl) * 2010-08-09 2014-10-30 Verona Pharma Plc Kristalinična oblika spojine PIRIMIDIO(6,1-A) IZOKINOLIN-4-ENA
CN107875127A (zh) * 2012-02-28 2018-04-06 艾塞尤提卡控股公司 可吸入药物组合物
ES2773142T3 (es) * 2014-05-12 2020-07-09 Verona Pharma Plc Nuevo tratamiento
LT3193835T (lt) * 2014-09-15 2018-06-11 Verona Pharma Plc Skysta inhaliuojama vaisto forma, apimanti rpl554

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105142638A (zh) * 2013-03-15 2015-12-09 维罗纳制药公司 药物组合
CN107406446A (zh) * 2015-02-11 2017-11-28 维罗纳制药公司 嘧啶并[6,1‑a]异喹啉‑4‑酮化合物的盐

Also Published As

Publication number Publication date
EP3820446B1 (en) 2021-11-03
US20210379053A1 (en) 2021-12-09
AU2019358585B2 (en) 2025-01-16
GB2578093A (en) 2020-04-22
CN112912064A (zh) 2021-06-04
PL3820446T3 (pl) 2022-03-14
JP2024113096A (ja) 2024-08-21
SMT202200044T1 (it) 2022-05-12
BR112021006712A2 (pt) 2021-07-27
PT3820446T (pt) 2021-12-03
WO2020074894A1 (en) 2020-04-16
SI3820446T1 (sl) 2022-01-31
CY1124943T1 (el) 2023-01-05
CA3113167A1 (en) 2020-04-16
KR20210073532A (ko) 2021-06-18
IL282032B1 (en) 2026-01-01
IL282032A (en) 2021-05-31
DK3820446T3 (da) 2021-12-06
ZA202102039B (en) 2022-08-31
ES2899744T3 (es) 2022-03-14
JP7578587B2 (ja) 2024-11-06
GB201816447D0 (en) 2018-11-28
US20250049781A1 (en) 2025-02-13
EP3960157A1 (en) 2022-03-02
GB2578093B (en) 2020-11-18
MY207302A (en) 2025-02-15
RS62775B1 (sr) 2022-01-31
MX2024001499A (es) 2024-02-27
EP3820446A1 (en) 2021-05-19
IL282032B2 (en) 2026-05-01
PH12021550767A1 (en) 2021-10-04
SG11202102567UA (en) 2021-04-29
AU2019358585A1 (en) 2021-04-15
HUE057780T2 (hu) 2022-06-28
JP2022513566A (ja) 2022-02-09
JP7836853B2 (ja) 2026-03-27
KR102960903B1 (ko) 2026-05-04
LT3820446T (lt) 2021-12-10
HRP20220053T1 (hr) 2022-04-15
MX2021003599A (es) 2021-05-28

Similar Documents

Publication Publication Date Title
JP7578587B2 (ja) Hfa-134a中のrpl554を含む吸入による投与用医薬組成物
US20060257324A1 (en) Pharmaceutical solution formulations for pressurised metered dose inhalers
US9655969B2 (en) Inhalable medicament comprising tiotropium
WO2000006121A1 (de) Medizinische aerosolformulierungen
JP2004525148A (ja) 医療用エアゾール配合物
JP2025148616A (ja) 改善された医薬エアゾール製剤
JP2007508283A (ja) カルボン酸界面活性剤を含むエアロゾル製剤
RU2582218C2 (ru) Способ получения дозирующего распыляющего ингалятора для лечения респираторного заболевания
EP1280532A1 (en) Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases
WO2021033081A1 (en) Stable aerosol composition for inhalation comprising glycopyrronium, formoterol and corticosteroid
US20200163955A1 (en) Sterile compositions of indacaterol suitable for nebulization
US20200215051A1 (en) Nebulization composition comprising tiotropium and indacaterol
WO2017089404A1 (en) Pharmaceutical composition
AU2021200396B2 (en) Pharmaceutical composition containing budesonide and formoterol
RU2813959C2 (ru) Фармацевтические композиции, содержащие RPL554 в HFA-134A для введения посредством ингаляции
HK40061834A (en) Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation
HK40042852A (en) Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation
HK40042852B (en) Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address

Address after: London City

Patentee after: Verona Pharmaceutical Co.,Ltd.

Country or region after: United Kingdom

Address before: cardiff uk

Patentee before: VERONA PHARMA PLC

Country or region before: United Kingdom